Warram Jason M, de Boer Esther, Sorace Anna G, Chung Thomas K, Kim Hyunki, Pleijhuis Rick G, van Dam Gooitzen M, Rosenthal Eben L
Department of Surgery, University of Alabama at Birmingham, Birmingham, AL, USA.
Cancer Metastasis Rev. 2014 Sep;33(2-3):809-22. doi: 10.1007/s10555-014-9505-5.
Although mainly developed for preclinical research and therapeutic use, antibodies have high antigen specificity, which can be used as a courier to selectively deliver a diagnostic probe or therapeutic agent to cancer. It is generally accepted that the optimal antigen for imaging will depend on both the expression in the tumor relative to normal tissue and the homogeneity of expression throughout the tumor mass and between patients. For the purpose of diagnostic imaging, novel antibodies can be developed to target antigens for disease detection, or current FDA-approved antibodies can be repurposed with the covalent addition of an imaging probe. Reuse of therapeutic antibodies for diagnostic purposes reduces translational costs since the safety profile of the antibody is well defined and the agent is already available under conditions suitable for human use. In this review, we will explore a wide range of antibodies and imaging modalities that are being translated to the clinic for cancer identification and surgical treatment.
尽管抗体主要是为临床前研究和治疗用途而开发的,但它具有高抗原特异性,可作为载体将诊断探针或治疗剂选择性地递送至癌症部位。人们普遍认为,用于成像的最佳抗原将取决于肿瘤相对于正常组织的表达情况以及整个肿瘤块内和患者之间表达的均匀性。为了进行诊断成像,可以开发新型抗体来靶向用于疾病检测的抗原,或者可以通过共价添加成像探针来重新利用目前已获美国食品药品监督管理局(FDA)批准的抗体。将治疗性抗体重新用于诊断目的可降低转化成本,因为抗体的安全性已明确界定,且该制剂已在适合人类使用的条件下可用。在本综述中,我们将探讨正在转化用于临床癌症识别和手术治疗的各种抗体和成像方式。